Author Index

Abels, J., 515
Abrahamson, G.M., 129
Abrahm, J., 502
Abramson, S., 25
Addison, I.E., 25, 150
Adler-Brecher, B., 410
Aiach, M., 87
Alarcón-Segovia, D., 568
Alexander, H.D., 287
Alter, B.P., 410
Alvarez, E., 410
An, E., 365
Anderson, C.C., 371
Anderson, G.J., 229
Angeloudi, M., 386
Archimbaud, E., 328
Asaoku, H., 523
Atkinson, K., 529
Auerbach, A.D., 410
Auld, P.W., 287

Baccarani, M., 460
Bachir, D., 117
Bandini, G., 486
Bail, S., 215
Bailly, M., 328
Bain, B., 301
Bara, L., 201
Barbui, T., 486
Barrett, A.J., 43
Barrowcliffe, T.W., 535
Bassan, R., 486
Battista, R., 486
Bauters, F., 497
Beard, J., 371
Beckford, M., 382
Bello-Fernandez, C., 237
Bennett, P.M., 392
Bernard, Ph., 127, 339
Berry, E., 191
Beuzard, Y., 117
Bevan, S.A., 535
Beylot, C., 128
Beylot, J., 128
Bierme, R., 282
Biggs, J., 529
Bignell, P., 559
Bilhou-Nabera, C., 339
Billiau, A., 32
Bjerrum, O.W., 73
Blench, I., 87
Blijham, G.H., 122
Bloom, A.L., 559
Bok, B., 201
Boultwood, J., 129
Bourdeau, M.J., 339
Bourrouillou, G., 282
Bowen, D., 419
Bowen, D.J., 559
Bowen, D.T., 296
Boyd, Y., 315
Brandt, E., 73
Brenner, B., 562
Brenner, M.K., 237, 259
Bresnihan, B., 255
Brisson-Lougarre, A., 282
Brito-Babapulle, V., 301
Broustet, A., 128, 339
Browett, P.J., 191
Bryckaert, M.-C., 80
Bruce, D., 360
Bungey, J., 43, 60
Bux, J., 121

Caillot, P., 346
Calero, M.A., 437
Calvo, F., 80, 431
Campbell, S.J., 354
Canepa, L., 123
Carotenuto, M., 50
Carrell, R.W., 360
Casale, R., 437
Casanova, F., 185
Caso, R., 87
Cassano, W., 466
Cassileth, P.A., 502
Castoldi, G.L., 66
Catovsky, D., 301
Chan, J.K.C., 509
Chase, A., 60
Chessells, J., 473
Chitkara, U., 410
Chow, F.-P.R., 139
Christakis, J., 386
Cines, D.B., 502
Ciolli, S., 180, 486
Coakham, H., 466
Colantonio, D., 437
Colas-Linhart, N., 201
Coles, G.A., 550
Collen, D., 261
Colombies, P., 282
Cony-Makhoul, P., 127, 339
Crawford, N., 209
Crescenti, C., 123
Crook, M., 209
Crouch, S., 158
Culligan, D., 419

Daly, M., 360
Damiani, D., 460
Dan, K., 365
David, B., 339
Davies, M.E., 550
Deane, M., 274
De Ceulaer, K., 382, 563
Deisseroth, A.B., 291
D'Emilio, E., 486
Dengler, H.J., 121
di Giorgio, G., 50
di Gregorio, P., 110
Diplock, A.T., 195
Di Prisco, U., 486
Djaldetti, M., 442
Dodds, A., 529
Doré, J.-F., 328
Doutre, M.S., 128
Dowding, C., 165
Downs, K., 529
Drach, J., 37
Dragon, A.C., 102
Duchayne, E., 282
Duncombe, A.S., 237
Dunn, D., 382

Edelstein, M., 502
Edgar, P.F., 360
Edson, J.R., 125
Ellegaard, J., 73
Endo, K., 561
Escribano, L.M., 437
Estey, E.H., 291
Evans, R.J., 535
Evensen, S.A., 73

Fabères, C., 339
Fagioli, F., 66
Faint, R.W., 539
Fanin, R., 460
Farr, C., 323
Fasola, G., 460
Feighery, C., 255
Fenaux, P., 497
Fenu, S., 491
Ferraris, A.M., 123
Ferrini, P.R., 180
Feuillatre-Fabre, F., 339
Finazzi, G., 87
Fletcher, J., 158
Foa, R., 491
Foures, C., 127
Francis, C.W., 562
Fraser, I.D., 221
Freyssinet, J.M., 87
Freedman, J.J., 567
Freedman, M.H., 410
Fricke, W., 575
Frissora, C.L., 410
Fujita, T., 250
Fukamachi, H., 54
Fuse, A., 32

Gaetani, G.F., 123
Gaillard, C.A., 122
Gallizia, C., 460
Garcia Suarez, J., 437
Gascón, A., 185
Gascoyne, S.C., 392
Gattringer, C., 37
Gavioli, R., 66
Gavosto, F., 491
Geary, C.G., 443, 447
Geromin, A., 460
Gibbons, B., 323
Gill, R., 323
Gimsing, P., 73
Girolami, A., 565
Glasmacher, A., 121
Göttsche, B., 546
Goldman, J.M., 60, 165
Goldschmeding, R., 398
González, M., 185
Gordon, M.Y., 165
Gorin, N.C., 127
Gottlieb, D.J., 237
Grandison, Y., 382
Grant, S., 5
Gratzer, W., 132
Gressin, R., 346
Grozdea, J., 282
Guerras, L., 185
Guiraud-Vitaux, F., 201
Guo, A-P., 165
Gutterman, J.U., 291

Hadley, A.G., 221
Hallett, J., 245
Halliday, J.W., 229
Halpérin, D.S., 410
Hamburger, A.W., 139
Hampton, K.K., 249
Hancock, J., 466
Hansen, M.M., 73
Harper, P.L., 360
Hart, M.G., 392
Harvath, L., 375
Hassan, J., 255
Hassapopoulou, H., 386
Hatamochi, A., 172
Hawkey, C.M., 392
Hayakawa, T., 424
Hedenus, M., 73
Hernández, J.M., 185
Heslop, H.E., 237
Hibi, S., 438
Higgs, D., 382
Hikiji, K., 250
Hillmen, P., 371
Hippe, E., 73
Hodges, E., 315
Hoffbrand, A.V., 237
Holmes, J.A., 130
Howe, C., 5
Howell, W.M., 315
Hows, J.M., 1, 60
Hoy, T., 260
Huang, A.T., 145
Huber, H., 37
Huhn, D., 453
Humphries, P., 257
Hutchinson, R.M., 436
Hutton, R.D., 550

Imai, N., 424
Imashuku, S., 438
Imbault, F., 201
Imoto, S., 250
Inatsuki, A., 311
Inokuchi, K., 365
Isenberg, D.A., 354
Ishikawa, H., 523
Itoh, M., 250
Iwato, K., 523

Jackson, F., 566
Jacob, M.-C., 346
Jacobs, A., 130, 296, 419
Jacobs, P., 245
Jalbert, P., 346
Jiang, C.-J., 247
Jiang, Y.Z., 43
Jimenez, R., 185
Johnson, B., 25, 150
Jouet, J.P., 497
Jungi, T.W., 16

Kakuda, H., 32
Kameoka, J., 561
Kantarjian, H.M., 291
Kar, B.C., 215
Katz, F., 323
Kawaguchi, T., 424
Kawamura, A., 424
Kawano, M., 523
Keating, M.J., 291
Keddari, E., 346
Keeling, D.M., 354
Keldsen, N., 73
Kemball-Cook, G., 535
Kemshead, J., 466
Khwaja, A., 25
King, P.H.M., 436
Kirkwood, J.K., 392
Klaassen, R.J.L., 93, 398, 403
Klein, H.G., 375
Kobayashi, Y., 311
Kontoghiorghes, G.J., 440
Krsnik, I., 437
Kulozik, A.E., 215
Kumpel, B.M., 221
Kuramoto, A., 523
Kusaka, M., 54
Kurzrock, R., 291

Lacombe, F., 339
Laforest, M.D., 201
Laine-Bidron, C., 80
Lamb, A.A., 567
Lampert, I.A., 301
Lane, D.A., 87
Lanza, F., 66
Laporte, J.Ph., 127
Lawler, M., 257
Lawlor, E., 566
Leader, K.A., 221

Leddy, J.P., 562
Le Marc'Hadour, F., 346
Leoni, F., 180, 486
Leroux, D., 346
Leven, R.M., 267
Lewis, S.M., 371
Liang, D.-C., 247
Lijnen, H.R., 261
Linch, D.C., 25, 150
Lindemans, J., 515
Littlewood, J.D., 535
Lombardi, G., 50
Loosveld, O.J.L., 122
Loukopoulos, D., 386
Luc Lai, J., 497
Luddington, R.J., 360
Lynch, L., 410

Macdonald, D., 43
Macdougall, I.C., 550
Machin, S., 209
Machin, S.J., 354, 539
Mackie, I.J., 354, 539
Mackinnon, S., 60
Magdelenat, H., 80, 431
Maisin, D., 165
Malavasi, F., 66
Malik, S., 260
Mallardi, F., 460
Maly, F.E., 16
Mandelli, F., 491
Mangoni, L., 486
Manoharan, A., 252
Marder, V.J., 562
Marin, J., 201
Marit, G., 127, 339
Markey, G.M., 287
Marsh, J.C.W., 447
Marshall, C.J., 323
Martin, J., 282
Martyré, M.-C., 80, 431
Mary, J.Y., 127
Masina, P., 110
Mason, K., 382
Matera, R., 50
Matteliano, S., 567
Matutes, E., 301
McCann, S.R., 257, 566
McCormick, J.A., 287
McCrady, C.W., 5
McCredie, K.B., 291
McGirl, A., 566
Meguro, K., 561
Mehta, A.B., 237
Melillo, L., 50
Meloni, G., 491
Merino, J.L., 437
Michelutti, A., 460
Michieli, M., 460
Miglino, M., 123
Mitchell, C., 259
Mizoguchi, H., 54
Modderman, P.W., 93
Modell, B., 132
Mold, N.G., 145
Montastruc, M., 339
Monteil, M., 346
Montserrat, E., 478
Morel, P., 497
Morgan, M., 529
Morilla, R., 43, 301
Moro, M[a] J., 185
Morra, E., 486
Morris, H.R., 87
Morris, J., 382
Morris, J.S., 386
Morris, T.C.M., 287
Motoji, T., 54
Mueller-Eckhardt, C., 121, 546
Musto, P., 50
Muta, K., 246

Nakagawa, T., 250
Nakao, Y., 250
Namba, M., 172
Nawata, H., 246
Nicola, N.A., 133
Nishimura, J., 246
Nishitani, K., 172
Nobuyoshi, M., 523
Nomura, T., 365
Norton, J.D., 274
Novarino, A., 491
Novitzky, N., 245
Nowell, P.C., 502

O'Brien, S., 291
Ockelford, P.A., 191
Ohtsuki, T., 172
Okuda, M., 561
Olds, R.J., 87
Olivieri, O., 117
Orfao, A., 185
Ortega, F., 185
Oshima, K., 54
Ouwehand, W.H., 93

Palva, I., 73
Panella, T.J., 145
Panico, M., 87
Papadopoulou, M., 386
Papanastassiou, V., 466
Pasqualetti, P., 437
Paulsen, W., 60
Peake, I.R., 559
Pearson, T.C., 371
Pelliniemi, T.-T., 335
Perera, F., 437
Pérez Rus, G., 437
Perona, G., 486
Perry, D.J., 360
Pettit, G.R., 5
Phillips, M., 473
Pieragostini, E., 110
Pileri, S., 460
Pizer, B., 466
Poole, G.D., 221
Portero, J.A., 185
Powell, L.W., 229
Prentice, H.G., 237
Prodouz, K., 375

Rahman, Y.E., 440
Rando, A., 110
Raspadori, D., 460
Reid, M.M., 443
Reiffers, J., 127, 128, 339
Reilly, J.T., 249
Reittie, J.E., 237
Remes, K., 335
Ricard, M.P., 437
Richards, S., 473
Robertz-Vaupel, G.-M., 121
Robinson, D., 301
Rodeghiero, F., 87
Rödjer, S., 73
Rodriguez, A., 267
Romero, M., 185
Rose, C., 497
Ross, P.J., 195
Rosse, W.F., 145
Rosti, G., 486
Royle, G., 191
Rozendaal, R., 398
Ruiz-Argüelles, A., 568
Ruiz-Argüelles, G.J., 568
Russo, D., 460
Ruthven, K., 25

Säuberlich, S., 453
Saitoh, S., 250
Sakai, A., 523
Sakai, K., 246
Salama, A., 546
Salti, F., 180
Samama, M., 201
Sanada, M., 256
Sánchez, J., 185
San Miguel, J.F., 185
Sanz, M.A., 185, 478
Sartori, M.T., 565
Sato, A., 561
Sato, T., 32
Scapoli, G.L., 486
Schey, S.A., 195
Schipperus, M.R., 515
Schouten, H.C., 122
Schreiber, A.D., 502
Schüepp, B., 16
Secker-Walker, L.M., 566
Serjeant, B.E., 215, 382, 386
Serjeant, G.E., 215, 382
Serjeant, G.R., 386, 563
Serke, S., 453
Shearer, M.J., 195
Shima, Y., 32
Shimosaka, A., 54
Shishido, T., 561
Simioni, P., 565
Sloand, E.M., 375
Sloand, J.A., 375
Smith, J.L., 315
Sonneveld, P., 515
Sotto, J.J., 346
Spisani, S., 66
Stadtmauer, E.A., 502
Staniswalis, J., 5
Stavem, P., 258
Sugawara, T., 561
Sutton, P.A., 139
Swirsky, D., 43
Szer, J., 529

Takai, K., 256
Talpaz, M., 291
Talstad, I., 73
Tanabe, O., 523
Tanaka, H., 523
Tazzari, P., 460
Tennant, G.B., 296
Teodori, P., 180
Thein, S.L., 87
Thomas, P., 559
Thompson, E.A., 87
Tien, H.-F., 247
Tienhaara, A., 335
Tijhuis, G.J., 93
Todeschini, G., 486
Tosti, S., 491
Traniello, S., 66
Trezzini, C., 16
Trouette, R., 339
Tsutsumi, M., 250
Tura, S., 486

Uzan, A., 201
Uzumaki, H., 54

Vallespi, T., 478
Van Damme, J., 32
van den Anker-Lugtenburg, P.J., 258
Van de Water, N.S., 191
van Lom, K., 515
van 't Veer, M.B., 258
Vavatsi, N., 386
Vezon, G., 127, 339
Vergnes, H., 282
Vestri, R., 110
Visani, G., 486
Vitoux, D., 117
Vlastuin, M., 515
Vlekke, A.B.J., 398, 403
von dem Borne, A.E.G.Kr., 93, 398, 403
Vulliamy, T., 43

Wainscoat, J.S., 129
Walsh, M.D., 229
Watanabe, M., 54
Waters, A.H., 570
Webb, C.E., 559
Webster, A.D.B., 150
Weisdorf, D.J., 125
West, R.R., 130
Westin, J., 73
Whelan, A., 255
Whitehouse, M., 444
Whittaker, J.A., 130
Williams, J.D., 550
Williamson, D., 360
Winship, P.R., 102
Wisløff, F., 73
Wodzinski, M.A., 249
Wong, K.F., 509

Yang, F., 110
Yasukawa, M., 311
Yawata, Y., 172
Yong, K., 25, 150
Yoshinaga, K., 561
Yu, M.W., 375

Zuffa, E., 486

Subject Index

Anaemia, aplastic, is it a pre-leukaemic disorder? 447
Anaemia, renal, rheological studies during treatment of, with recombinant human erythropoietin (MacDougall *et al*), 550
Anaemia, severe aplastic: the patient without a HLA-identical sibling (Hows), 1
Angioedema during therapy with recombinant tissue plasminogen activator (Francis *et al*), 562
Antithrombin variants, dysfunctional, the incidence of: four cases in 210 patients with thromboembolic disease (Harper *et al*), 360
Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate (Caso *et al*), 87
Aplastic pancytopenia instead of the misnomer aplastic anaemia (Stavem), 258
Autoimmune thrombocytopenic purpura, reduced erythrocyte complement receptor type 1 in (Muta *et al*), 246

Book reviews
Bone-marrow Transplantation in Children, 259

Cellular and Molecular Biology of Normal and Abnormal Erythroid Membranes, 132
Clinical Immunohematology: Basic concepts and clinical applications, 570
Flow Cytometry and Cell Sorting, 260
Hodgkin's Disease: the Consequences of Survival, 443
Leukaemia Diagnosis: a Guide to the FAB Classification, 443
Mechanisms of Action and Therapeutic Applications of Biologicals in Cancer and Immune Deficiency Disorders, 260
Molecular Control of Haemopoiesis, 259
Pathology of Thalassaemic Diseases, 132
The Lymphoid Leukaemias, 443
Busulphan and cyclophosphamide, the toxicity of, as the preparative regimen for bone marrow transplantation (MORGAN *et al*), 529

CD34$^+$-cells, circulating, multiparameter flow-cytometrical quantitation of: correlation to the quantitation of circulating haemopoietic progenitor cells by *in vitro* colony-assay (SERKE *et al*), 453
Chimaerism, mixed (MCCANN *et al*), 257
Chromosomal deletion breakpoints, practical considerations in the analysis of, by pulsed field gel electrophoresis (ABRAHAMSON *et al*), 129
Cirrhosis, primary biliary, autoimmune neutropenia due to NA1 specific antibodies in (BUX *et al*), 121
c-myc gene, increased expression of, may be related to the aggressive transformation of human myeloma cells (NOBUYOSHI *et al*), 523
Colony-stimulating factors, receptors for (NICOLA), 133
Cyclophosphamide and busulphan, the toxicity of, as the preparative regimen for bone marrow transplantation (MORGAN *et al*), 529
Cytokines in haemophagocytic syndrome (IMASHUKU & HIBI), 438

Danazol treatment of myelodysplastic syndromes (STADTMAUER *et al*), 502
Diclofenac-induced immune haemolysis, autoantibodies and drug- or metabolite-dependent antibodies in patients with (SALAMA *et al*), 546
1,2-Dimethyl-3-hydroxypyrid-4-one (L1), oral, in different ferrikinetic models in animals and humans, assessment of (KONTOGHIORGHES & RAHMAN), 440
DNA polymorphisms within the human factor IX gene, three, facile and rapid analysis of, using the polymerase chain reaction (BOWEN *et al.*), 559

Erythrocyte size, number and haemoglobin content in vertebrates (HAWKEY *et al*), 392
Erythropoietin, sensitivity of erythroid progenitor colonies to, in azido thymidine treated immunodeficient mice (CHOW *et al*), 139
Erythropoietin, simple *in vivo* bioassay for (KAWAMURA *et al*), 424

Fanconi's anaemia and pregnancy (ALTER *et al*), 410
Factor VIII, human, from different sources by human factor VIII inhibitors, variable inactivation of (LITTLEWOOD *et al*), 535
Factor XIII defect, an updated classification of (GIROLAMI *et al*), 565
Fibrinogen, evidence that exposure to, or to antibodies directed against Mac-1 (CD11b/CD18; CR3) modulates human monocyte effector functions (TREZZINI *et al*), 16
Fibrinolytic responses to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus (KEELING *et al*), 354

α-globin genes in sheep, expression of triplicated and quadruplicated (VESTRI *et al*), 110
Granulocyte colony-stimulating factor (G-CSF) receptors on acute myeloblastic leukaemia cells and their relationship with the proliferative response to G-CSF in clonogenic assay (MOTOJI *et al*), 54

Haemoglobins, abnormal, detection by the Sysmex NE-8000 automated cell counter (LAMB *et al*), 567
Haemolytic disease of the newborn, correlation of serological, quantitative and cell-mediated functional assays of maternal alloantibodies with the severity of (HADLEY *et al*), 221
Haemophilia B Leyden arising *de novo* by point mutation in the putative factor IX promoter region (ROYLE *et al*), 191
Haemophilia B patients with mutations in the two calcium binding domains of factor IX, identification of: importance of a β-OH Asp→Asn change (WINSHIP & DRAGON), 102
Heparin, technetium 99m labelled standard, pharmacokinetics and biodistribution of, and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers (LAFOREST *et al*), 201
Hypereosinophilic syndrome, alpha-interferon in a case of (VAN DEN AMKER-LUGTENBURG & VAN 'T VEER), 258

Idiopathic thrombocytopenic purpura, electrokinetic properties and surface membrane sialic acid status of platelets in (CROOK *et al*), 209
Immunoglobulin gene 'fingerprinting': an approach to analysis of B lymphoid clonality in lymphoproliferative disorders (DEANE & NORTON), 274
Immunoglobulins of different class and subclass, platelet-bound, quantification of, using radiolabelled monoclonal antibodies: assay conditions and clinical application (TIJHUIS *et al*), 93
Interferon-α, the effects on the proliferation of CML progenitor cells *in vitro* are not related to the precise position of the M-BCR breakpoint (DOWDING *et al*), 165
Interferon-γ *in vivo* reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-B in patients with myelofibrosis with myeloid metaplasia (MARTYRÉ *et al*), 431
Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation (HESLOP *et al*), 237
Interleukin 2, recombinant, treatment of acute myeloid leukaemia patients with: a pilot study (FOA *et al*), 491
Interleukin 6, a possible autocrine growth and differentiation factor for the human megakaryocytic cell line, CMK (FUSE *et al*), 32
Interleukin-6 and Interleukin-1 enhancement of GM-CSF-dependent proliferation of haematopoietic progenitor cells in myelodysplastic syndromes (SCHIPPERUS *et al*), 515
Interleukin-6, recombinant, effect on size, ploidy and cytoplasmic fragmentation, immunomagnetic bead isolation of megakaryocytes from guinea-pig bone marrow (LEVEN & RODRIGUEZ), 267

K^+ efflux in deoxygenated sickle cells in the presence or absence of DIOA, a specific inhibitor of the [K^+, Cl^-] cotransport system (OLIVIERI *et al*), 117

Lactoferrin inducible monocyte cytotoxicity defective in esterase deficient monocytes (MCCORMICK *et al*), 287
Leucocyte integrins, role in phagocyte responses to granulocyte-macrophage colony stimulating factor (GM-CSF): *in vitro* and *in vivo* studies on leucocyte adhesion deficiency neutrophils (YONG *et al*), 150
Leukaemia, acute 'bilineal-biphenotypic' (LAWLOR *et al*), 566
Leukaemia, acute, combined flow cytometric assessment of cell surface antigens and nuclear TdT for the detection of minimal residual disease in (DRACH *et al*), 37
Leukaemia, acute, folinic acid and peripheral blood stem cell collection in patients with (REIFFERS *et al*), 127
Leukaemia, acute myeloblastic, correlation of MDR status with clinical outcome in patients with (HOLMES *et al*), 130
Leukaemia, acute myelogenous, inducibility of lymphokine activated killer (LAK) cells in patients with, in complete remission and its clinical relevance (ARCHIMBAUD *et al*), 328
Leukaemia, acute myelogenous, long-term outcome of adults with: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years (BANDINI *et al*), 486
Leukaemia, acute myeloid, complete remission in, after treatment with recombinant human granulocyte colony-stimulating factor and high dose intravenous methylprednisolone (SUGAWARA *et al*), 561
Leukaemia, acute myeloid, in childhood: the costs and benefits of intensive treatment (PHILLIPS *et al*), 473

Leukaemia, acute myeloid, relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor (MACDONALD *et al*), 43
Leukaemia as a manifestation of large cell lymphoma (BAIN *et al*), 301
Leukaemia, B-cell chronic lymphocytic, the expression of the multidrug resistance-associated glycoprotein in (MICHIELI *et al*), 460
Leukaemia, central nervous system, in children, a pilot study of monoclonal antibody targeted radiotherapy in (PIZER *et al*), 466
Leukaemia, childhood myeloid, analysis of *ras* gene mutations in (FARR *et al*), 323
Leukaemia, chronic granulocytic, in transformation, autologous blood stem cell transplantation for: a report of 47 cases (REIFFERS *et al*), 339
Leukaemia, chronic lymphocytic: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients (VALLESPI *et al*), 478
Leukaemia, chronic myeloid, evaluation of CR1 expression in neutrophils from: relationship between prognosis and cellular activity (LANZA *et al*), 66
Leukaemia, chronic myeloid, origin and function of adherent lymphokine activated killer cells in patients with, who relapse following bone marrow transplantation (MACKINNON *et al*), 60
Leukaemia, megakaryoblastic, chromosomal abnormalities, elevated platelet count and thrombin complications in (NOVITZKY *et al*), 245
Leukaemoid proliferation, neonatal transient, followed by acute myeloid leukaemia in a phenotypically normal child (JIANG *et al*), 247

Macrophage colony-stimulating factor, *in vivo* effects of, on human monocyte function (KHWAJA *et al*), 25
Mastocytosis, generalized, blood findings in: coexistent non-Hodgkin's lymphoma (KING & HUTCHINSON), 436
Mastocytosis, systemic, and primary thrombocythaemia (KRSNIK *et al*), 437
Megakaryocytes, 'dysplastic' and hypogranular, are they specific markers for myelodysplastic syndrome? (WONG & CHAN), 509
Mononuclear cells, stimulated, the priming effects of the products of, on the response of neutrophils to c5a des arg (CROUCH & FLETCHER), 158
Mononucleosis, infectious, elevated T cell receptor $\gamma\delta+$ T cells in patients with (HASSAN *et al*), 255
Multiple myeloma, alpha interferon raises serum beta-2-microglobulin in patients with (TIENHAARA *et al*), 335
Mylodysplasia, high-risk, colony-cluster ratio and cluster number in cultures of circulating myeloid progenitors as indicators of (TENNANT *et al*), 296
Myelodysplastic syndrome, loss of multiple point mutations of *RAS* genes associated with acquisition of chromosomal abnormalities during disease progression in (NAKAGAWA *et al*), 250
Myelodysplastic syndromes, adult *de novo*, treated by intensive chemotherapy, prognostic factors in (FENAUX *et al*), 497
Myelodysplastic syndromes, effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with (ESTEY *et al*), 291
Myelodysplastic syndromes, the treatment of anaemia in, with recombinant human erythropoietin (BOWEN *et al*), 419
Myelofibrosis with intermittent hydroxyurea, management of (MANOHARAN), 252
Myelofibrosis with myeloid metaplasia, increased intraplatelet levels of platelet-derived growth factor-B in patients with (MARTYRÉ *et al*), 80
Myeloma, advanced refractory, teniposide, dexamethasone and continuous-infusion cyclophosphamide in (LEONI *et al*), 180
Myeloma cell lines, five human, analysis of methylation in the c-*MYC* gene in (OHTSUKI *et al*), 172
Myeloma cells, nuclear hypersegmentation in (DJALDETTI), 442
Myeloma, multiple, immunophenotypic heterogeneity of: influence on the biology and clinical course of the disease (SAN MIGUEL *et al*), 185
Myeloma, multiple, polyclonal pattern of X-inactivation in (GAETANI *et al*), 123
Myeloma, multiple, the 'β_2-microglobulin index' in the prognostic evaluation of (PASQUALETTI *et al*), 437
Myelomatosis, refractory, treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study (GIMSING *et al*), 73

Neutropenia, acquired chronic, differential effect of G-CSF and GM-CSF in (WODZINSKI *et al*), 249
Neutrophil alkaline phosphatase, difference in activity properties and subcellular distribution of, between normal individuals and patients with trisomy 21 (GROZDEA *et al*), 282
Neutrophil-bound antibodies and immune complexes, differentiation between (KLAASSEN *et al*), 398
Neutrophil-bound immunoglobulin in HIV infection is of autoantibody nature (KLAASSEN *et al*), 403
Non-Hodgkin's lymphomas with t(11;14)(q13;q32): a subset of mantle zone/intermediate lymphocytic lymphoma? (LEROUX *et al*), 346

P-glycoprotein positive cells in complete remission, multidrug resistance associated, high risk of early resistant relapse for leukaemic patients with presence of (MUSTO *et al*), 50
Phosphatidylinositol (PI)-linked proteins in a very early human multipotential haematopoietic marrow cell, absence of (HUANG *et al*), 145
Piroxicam associated with aplastic anaemia (SANADA & TAKAI), 256
Platelet aggregation is inhibited by a nitric oxide-like factor released from human neutrophils *in vitro* (FAINT *et al*), 539
Prednisone, acute tumour lysis syndrome in a patient with acute lymphoblastic leukaemia after a single dose of (LOOSVELD *et al*), 122
Protein C/S system, possible mechanisms on the relationship of antiphospholipid antibodies and deficiencies of (RUIZ-ARGÜELLES *et al*), 568
Protein kinase C, effect of phamacologic manipulation of, by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF (MCCRADY *et al*), 5

Sickle cell–β^+ thalassaemia in Orissa State, India (KULOZIK *et al*), 215
Sickle cell disease, acute splenic sequestration in Jamaican adults with: a role of alpha thalassaemia (DE CEULAER & SERJEANT), 563
Sickle cell disease, homozygous, after the age of 40 years, the haematology of (MORRIS *et al*), 382
Sickle cell syndromes in Northern Greece, a comparison of (CHRISTAKIS *et al*), 386

T cell leukaemia virus type I infection, human, the effect on a herpes simplex virus-specific $CD8^+$ cytotoxic T cell clone (INATSUKI *et al*), 311
Thrombocythaemia, primary, in pregnancy (BEARD *et al*), 371
Thrombocytopenia, cell-mediated cyclic, treated with azathioprine (DAN *et al*), 365
Thrombolytic agents, improved, towards the development of (LIJNEN & COLLEN), 261
Transferrin receptors, intestinal, and iron absorption in the neonatal rat (ANDERSON *et al*), 229

Uraemia, reduction of platelet glycoprotein Ib in (SLOAND *et al*), 375

Vasculitis, cutaneous, with myelodysplastic syndromes (DOUTRE *et al*), 128
Venous thrombosis, recurrent, associated with inherited deficiency of heparin cofactor II (WEISDORF & EDSON), 125
Vitamin K metabolism, a fibroblast cell culture model to study, and the inhibition of vitamin K epoxide reductase by known and suspected antagonists (ROSS *et al*), 195

X-chromosome DNA methylation patterns, variable, detected with probe M27β in a series of lymphoid and myeloid malignancies (HODGES *et al*), 315